129 related articles for article (PubMed ID: 17297412)
21. [Treatment of hepatitis C virus infection].
Zeuzem S
Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
[TBL] [Abstract][Full Text] [Related]
22. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
23. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
[TBL] [Abstract][Full Text] [Related]
24. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
Kornberg A; Küpper B; Tannapfel A; Thrum K; Bärthel E; Habrecht O; Settmacher U
Transplantation; 2008 Aug; 86(3):469-73. PubMed ID: 18698252
[TBL] [Abstract][Full Text] [Related]
25. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
[TBL] [Abstract][Full Text] [Related]
26. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
27. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
[TBL] [Abstract][Full Text] [Related]
28. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
29. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
31. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].
Berak H; Kołakowska-Rzadzka A; Wasilewski M; Stańczak JJ; Krzysztof B; Walewska-Zielecka B; Horban A
Przegl Epidemiol; 2006; 60(4):673-6. PubMed ID: 17682747
[TBL] [Abstract][Full Text] [Related]
33. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
Zarski JP; Sturm N; Desmorat H; Melin P; Raabe JJ; Bonny C; Sogni P; Pinta A; Rouanet S; Babany G; Cheveau A; Chevallier M
Liver Int; 2010 Aug; 30(7):1049-58. PubMed ID: 20492512
[TBL] [Abstract][Full Text] [Related]
34. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
[TBL] [Abstract][Full Text] [Related]
35. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
36. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
del Valle J; Mira JA; de los Santos I; López-Cortés LF; Merino D; Rivero A; Girón JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Pineda JA
AIDS; 2008 May; 22(8):923-30. PubMed ID: 18453851
[TBL] [Abstract][Full Text] [Related]
37. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C;
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533
[TBL] [Abstract][Full Text] [Related]
38. [ANRS HC 02 RIBAVIC: histo-pathological impact].
Pol S
Gastroenterol Clin Biol; 2009 Mar; 33 Suppl 2():S106-9. PubMed ID: 19375037
[TBL] [Abstract][Full Text] [Related]
39. Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology.
Kornberg A; Küpper B; Tannapfel A; Thrum K; Bärthel E; Settmacher U
Liver Int; 2006 Sep; 26(7):811-6. PubMed ID: 16911463
[TBL] [Abstract][Full Text] [Related]
40. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
Veldt BJ; Heathcote EJ; Wedemeyer H; Reichen J; Hofmann WP; Zeuzem S; Manns MP; Hansen BE; Schalm SW; Janssen HL
Ann Intern Med; 2007 Nov; 147(10):677-84. PubMed ID: 18025443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
